BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 23, 2003
View Archived Issues
Millennium Files For Approval Of Velcade In Multiple Myeloma
Millennium Pharmaceuticals Inc. filed a new drug application for Velcade, a proteasome inhibitor shown to extend median survival time in relapsed and refractory multiple myeloma patients to 16.4 months. (BioWorld Today)
Read More
Geron Reducing Staff Again To Push Lead Cancer Drug
Read More
From Bone Marrow Transplant To Brain Targets, Patient Autopsies See Stem Cells Creating Neurons
Read More
Amgen Files For Approval Of Enbrel In Ankylosing Spondylitis
Read More
Anthrax/Plague Vaccine Funds Will Help Avant With Pipeline
Read More
Other News To Note
Read More